NIFTYMID150 Archives - ChartAlert®

APARINDS – Apar Industries – Q4 FY26 Earnings Call – 28-May-26

APARINDS/ Apar Industries’ topline resilient (domestic + U.S. data centers), bottomline sensitive to metal/FX volatility, margins anchored by premium mix and capex efficiency.

1–2 minutes

Also see: APARINDS – Apar Industries – Q4 FY26 Financial Results – 28-May-26

3-Scenario Framework

📊 Base Case (60% Probability)

Key Variables: Metal prices stabilize (aluminum premiums $300–350/ton), U.S. tariffs remain, HVDC orders materialize in FY27–FY28.
Outlook: Revenue CAGR 15–20% (driven by Conductor/Cable), EBITDA/ton INR35,000–38,000 (premium mix >50%). U.S. contributes 10–15% of revenue by FY28. Capex ROI visible in FY28–FY29.

APARINDS – Apar Industries – Q4 FY26 Financial Results – 28-May-26

Apar Industries’ FY26 confirms volume‑led growth in Conductors/Cables, but ₹1,867 Cr WC build compressed OCF. Re‑rating hinges on FY27 receivables recovery and FCF re‑expansion; margin watch: 30 bps segment compression and 60% unallocable cost spike. Capacity‑constrained compounder — monitor DSO trends and CWIP activation quarterly.

1–2 minutes

🔍 Observations

Topline

Revenue from Operations jumped 23.3% YoY (₹18,581 Cr → ₹22,902 Cr), with Q4FY26 alone clocking ₹6,603 Cr — the strongest quarter of the year, up 26.7% YoY.
Conductors dominated at ₹12,712 Cr (55% of segment revenue), growing 32.7% YoY; Cables surged 25.8% YoY to ₹6,220 Cr — both segments accelerating meaningfully.
Transformer & Speciality Oils grew a modest 5.6% YoY to ₹5,373 Cr, acting as the revenue drag relative to peer segments.

Bottomline

PAT grew 18.9% YoY (₹821 Cr → ₹977 Cr); EPS rose from ₹204.47 to ₹243.21 — a clean, unlevered earnings expansion.
Exceptional items of ₹32.53 Cr (net charge) dented reported PBT in FY26; pre-exceptional PBT grew 21.4% YoY (₹1,106 Cr → ₹1,342 Cr), a more accurate read of operating performance.
Q4FY26 PAT of ₹253 Cr was flattish YoY (vs. ₹250 Cr in Q4FY25) despite a 27% revenue jump — margin compression at the quarterly level warrants watching.

Margins

Segment EBIT margin (Total Segment Results / Total Segment Revenue): FY26 = ₹1,968 Cr / ₹24,501 Cr = 8.0% vs. FY25 = ₹1,634 Cr / ₹19,757 Cr = 8.3% — a 30 bps compression despite absolute profit growth.
Net profit margin contracted slightly: FY26 = ₹977 Cr / ₹22,902 Cr = 4.27% vs. FY25 = ₹821 Cr / ₹18,581 Cr = 4.42% — scale is outrunning margin expansion.
Unallocable expenses ballooned 60.6% YoY (₹117 Cr → ₹189 Cr), the primary margin headwind at the PBT level.

Growth Trajectory

3-year revenue CAGR implied from FY25→FY26 base is strong; the 23% single-year step-up on an already ₹18,581 Cr base signals Apar is capturing the T&D capex upcycle, not just riding it.
Cables segment re-rating underway — grew from ₹4,945 Cr to ₹6,220 Cr (+25.8%) with EBIT jumping 29.5% (₹459 Cr → ₹595 Cr), margin holding near 9.6%.
Conductor EBIT grew 21.9% YoY on 32.7% revenue growth, implying mild margin dilution — likely mix/pricing pressure as volumes scale into commodity-linked orders.

SYNGENE – Syngene International – Q4 FY26 Earnings Call – 30-Apr-26

SYNGENE’s topline resilience hinges on CDMO ramp-up and Librela dissipation, while margins remain range-bound (mid-20s) until facility utilization inflects; cash flow strength provides downside protection.

1–2 minutes

Also see: SYNGENE – Syngene International – Q4 FY26 Financial Results – 29-Apr-26

3-Scenario Framework

📊 Base Case (50% Probability)

Librela headwinds fully absorbed by FY27 end, with H2 FY27 revenue inflection driven by new CDMO contracts and stabilized research services. EBITDA margins hover in mid-20s as Bayview/Unit 3 costs offset utilization gains. Free cash flow remains robust (~INR500 crore annually), supporting capex and potential shareholder returns.

SYNGENE – Syngene International – Q4 FY26 Financial Results – 29-Apr-26

Syngene’s FY26 saw 2.6% revenue growth and 36% profit fall, with 400–500 bps margin hit from forex/employee costs. Strong FCF and near‑zero debt provide balance sheet comfort. Q4 recovery hints charges easing, but sustained EBITDA >28% hinges on cost discipline and hedging restructure.

1–2 minutes

🔍 Observations

Topline

FY26 revenue grew 2.6% YoY (₹36,424M → ₹37,387M) — modest, indicating demand stabilisation rather than acceleration; Q4FY26 added ₹10,365M vs ₹10,180M in Q4FY25, a 1.8% quarterly comp.
Sequential Q4 bounce of 13% (₹9,171M → ₹10,365M) signals some seasonality recovery after a soft Q3.
Revenue growth materially trails cost growth — total expenses rose 7.6% YoY vs revenue’s 2.6%, squeezing every margin line.

Bottomline

FY26 PAT collapsed 36.2% YoY (₹4,962M → ₹3,167M), driven by cost inflation, a ₹766M net exceptional loss, and a ₹590M forex drag vs near-neutral ₹19M in FY25.
Excluding exceptionals, PBT fell 22.4% (₹6,279M → ₹4,875M) — underlying operations deteriorated significantly, not just optics.
Q4FY26 PAT at ₹1,479M vs ₹1,833M in Q4FY25 (-19.3%) confirms the weakness persists into year-end.

Margins

EBITDA proxy (PBT before exceptionals + D&A + Finance costs): FY26 = ₹4,875 + ₹4,529 + ₹488 = ₹9,892M; FY25 = ₹6,279 + ₹4,326 + ₹531 = ₹11,136M. EBITDA margin: FY26 = 26.5% vs FY25 = 30.6% — a 410 bps contraction.
Net profit margin: FY26 = 8.5% (₹3,167M ÷ ₹37,387M) vs FY25 = 13.6% (₹4,962M ÷ ₹36,424M) — 510 bps erosion.
Employee costs surged 12.3% YoY (₹9,839M → ₹11,049M), now representing 29.6% of revenue vs 27.0% in FY25 — the single largest margin headwind.

Growth Trajectory

Two-year revenue trajectory is nearly flat: FY25 grew off a likely stronger FY24 base; FY26 adds only ₹963M incremental — structural growth slowdown is apparent.
EPS declined 36.3% YoY (₹12.35 → ₹7.87), compressing shareholder returns sharply and raising questions about near-term re-rating potential.
Capex is decelerating — PP&E purchases dropped from ₹7,603M (FY25) to ₹3,440M (FY26), suggesting the investment cycle is maturing; growth acceleration from new capacity depends on utilisation ramp.

APARINDS – Q3 FY26 Earnings Call – 29-Jan-26

APARINDS’ topline likely tracks 20%+ CAGR on domestic resilience (renewables, railways, data centers) and U.S. order rebound, but margins face 100–150 bps compression from tariffs/commodities; bottomline hinges on capex utilization timing and transmission catch-up in H2 FY26.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: U.S. tariffs ease in H2 FY27; transmission additions catch up in Q4 (government concessions); commodity prices stabilize.
Outcome: Cable revenue grows 20–22% (INR 500 crore U.S. orders executed); conductor volumes at 8–9%. EBITDA margins hold at 9.5–10%. Capex utilization ramps in FY28; ROIC 12–14%. EPS grows 15–18% YoY, tracking guidance.

SYNGENE – Q3 FY26 Earnings Call – 23-Jan-26

SYNGENE’s topline faces near-term headwinds from single-product concentration, but diversification efforts (BMS, Bayview, clinical trials) could stabilize revenue by FY27; margins hinge on CDMO utilization and cost discipline, with EBITDA recovery lagging revenue by 12–18 months. Cash flow remains resilient but vulnerable to CAPEX overruns or prolonged revenue drag.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Librela stabilizes by H2 FY27, with partial revenue recovery (50% of lost run-rate). CDMO utilization reaches 60–70% in Mangalore/Bayview, driven by 1–2 new large-molecule contracts. Research services grow 8–10%, supported by biotech funding. FY27 revenue flat to +2%, EBITDA margins 23–25%.
Trigger: Zoetis resolves product issues; Syngene secures $20–30M annual CDMO contracts.